Knott David M Jr Grows Position in Day One Biopharmaceuticals, Inc. $DAWN

Knott David M Jr raised its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 287.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 130,500 shares of the company’s stock after purchasing an additional 96,786 shares during the period. Knott David M Jr owned 0.13% of Day One Biopharmaceuticals worth $920,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. ProShare Advisors LLC raised its stake in shares of Day One Biopharmaceuticals by 12.9% in the second quarter. ProShare Advisors LLC now owns 18,545 shares of the company’s stock worth $121,000 after buying an additional 2,121 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Day One Biopharmaceuticals by 6.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,992 shares of the company’s stock worth $302,000 after acquiring an additional 2,149 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in Day One Biopharmaceuticals by 44.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after acquiring an additional 2,264 shares in the last quarter. Teacher Retirement System of Texas raised its stake in Day One Biopharmaceuticals by 18.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 17,721 shares of the company’s stock worth $115,000 after acquiring an additional 2,750 shares during the period. Finally, Pale Fire Capital SE raised its stake in Day One Biopharmaceuticals by 9.9% during the 2nd quarter. Pale Fire Capital SE now owns 34,843 shares of the company’s stock worth $226,000 after acquiring an additional 3,150 shares during the period. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Performance

DAWN stock opened at $21.20 on Friday. The company’s fifty day moving average price is $11.10 and its 200-day moving average price is $9.05. Day One Biopharmaceuticals, Inc. has a one year low of $5.64 and a one year high of $21.23. The company has a market capitalization of $2.19 billion, a PE ratio of -20.58 and a beta of -1.25.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). The company had revenue of $53.72 million during the quarter, compared to the consensus estimate of $49.81 million. Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. On average, research analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on DAWN shares. TD Cowen cut shares of Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. HC Wainwright cut their price target on Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. JonesTrading reissued a “hold” rating and set a $21.50 price target (up from $20.00) on shares of Day One Biopharmaceuticals in a report on Friday. Needham & Company LLC restated a “hold” rating on shares of Day One Biopharmaceuticals in a research report on Friday. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Friday. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $25.56.

Insider Transactions at Day One Biopharmaceuticals

In related news, CEO Jeremy Bender sold 15,459 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $179,324.40. Following the completion of the transaction, the chief executive officer directly owned 204,603 shares of the company’s stock, valued at approximately $2,373,394.80. This represents a 7.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Michael Vasconcelles sold 2,728 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $31,644.80. Following the transaction, the insider owned 4,397 shares of the company’s stock, valued at $51,005.20. This represents a 38.29% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 36,461 shares of company stock valued at $422,948. 6.20% of the stock is owned by insiders.

Trending Headlines about Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Acquisition announced — Servier agreed to buy Day One for $21.50 per share in cash (~$2.5 billion), a deal that crystallizes a takeover premium and explains the sharp rally; the transaction is subject to customary closing conditions and is expected to close in Q2 2026. Article Title
• Positive Sentiment: Analyst target raised — JonesTrading reiterated a “hold” but increased its price target to $21.50 (from $20.00), putting its target in line with the buyout price and reinforcing the deal valuation. Article Title
• Positive Sentiment: Options and volume spike — Unusual call-option activity and extremely high trading volume point to takeover-driven speculative buying and arbitrage interest ahead of the deal close (increased open interest and buy-side activity tend to amplify intraday moves).
• Neutral Sentiment: Trading halt — Shares were temporarily halted earlier for “News pending,” a standard market pause when material corporate announcements are imminent; this is procedural and common around M&A.
• Neutral Sentiment: Ratings reaffirmed — Needham and JonesTrading reaffirmed their “hold” ratings (Needham also maintained its view) even as price targets moved; these keep analyst sentiment mixed despite the takeover. Article Title
• Negative Sentiment: Multiple shareholder investigations and potential litigation — Several law firms (e.g., Brodsky & Smith, Ademi LLP, Halper Sadeh, Monteverde & Associates) announced probes into whether the Board obtained a fair price and followed a proper process; lawsuits or injunctions could delay closing, increase deal costs, or put pressure on the eventual net proceeds to shareholders. Article Title Article Title

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.